Clinical information
Diagnostic Utility:
This is the qualitative detection of IgM antibodies against the core antigen of hepatitis B virus (IgM anti-HBc), and its determination is useful in:
- Detection of acute hepatitis B virus infection.
- Transfusion of blood components.
- Transplantation of progenitor cells, umbilical cord blood, solid organs, and tissues.
Method:
Chemiluminescent Microparticle Immunoassay (CMIA).
Reference Values
Possible results are: Reactive and Non-reactive.
Diagnostic Algorithm:
Not applicable.
Response Time:
Maximum of 2 working days.
Specimen information
Sample: Serum and/or plasma
Tube: 1-5 mL aliquots, plasma tubes with EDTA, sodium citrate, sodium heparin, ACD, CPDA-1, CPD, or potassium oxalate as an anticoagulant and/or serum tubes with or without gel separator.
Minimum essential volume: 1 ml
Stability:
- At room temperature: ≤ 3 days
- In refrigeration 2-8 ºC: ≤ 14 days
- Sample frozen at or below -20ºC: 10 years
Transport instructions: Preferably at room temperature if they are total blood tubes and refrigerated if they are serum and/or plasma aliquots.
Reason for rejection: Sample highly hemolyzed
Administrative information
BST Code: 0160
Test Description: Anti-
Synonyms: Anti-HBc IgM
Section: Transfusion Safety Laboratory
BST Rate: Check the updated rates here.
Profiles:
The test for antibodies against the core protein of HBV can be requested alone or as part of the profile:
| Profile | Included Tests |
|---|---|
| HBV Hepatitis B virus antibodies detection profile |
106 Anti-HBc II. Screening 100 Anti-HBs. Screening 160 Anti-HBcIgM. Screening |
References
- Inserts kits de Anti-HBc IgM Architect, Abbott.
Quality
BST holds ISO 9001, ISO 14001, and OSHAS 18001 quality certifications, as well as the European Excellence 500+ seal. BST is accredited by CAT, JACIE-FACT, FACT-NETCORD, and EFI, and complies with Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) guidelines.